Piperacillin and Tazobactam Injection

Piperacillin and tazobactam injection is approved to treat a range of serious bacterial infections. Coverage and patient eligibility vary by the specific use:

• Intra-abdominal infections (including complicated appendicitis with rupture or abscess, and peritonitis) — in adults and children 2 months of age and older
• Hospital-acquired (nosocomial) pneumonia, moderate to severe — in adults and children 2 months of age and older; when caused by Pseudomonas aeruginosa, must be combined with an aminoglycoside antibiotic
• Community-acquired pneumonia of moderate severity — in adults only, when caused by Haemophilus influenzae
• Skin and skin structure infections (including cellulitis, cutaneous abscesses, and ischemic/diabetic foot infections) — in adults only
• Female pelvic infections (postpartum endometritis and pelvic inflammatory disease) — in adults only
• It should only be used when the infection is proven or strongly suspected to be caused by susceptible bacteria, to help prevent antibiotic resistance.

Piperacillin is a penicillin-class antibiotic that kills bacteria by blocking the construction of their cell walls — without an intact cell wall, bacteria cannot survive. Tazobactam does not kill bacteria on its own, but it acts as a shield: it inhibits beta-lactamases, which are enzymes that some bacteria use to destroy penicillin-type antibiotics. By blocking these enzymes, tazobactam allows piperacillin to stay active against a wider range of bacteria, including strains that would otherwise be resistant.

The combination is effective against a broad spectrum of gram-positive and gram-negative bacteria, both aerobic (oxygen-using) and anaerobic (non-oxygen-using). How well the combination works is closely tied to how long the drug concentration in the body stays above the minimum level needed to inhibit bacterial growth.

Piperacillin and tazobactam injection is given only by intravenous (IV) infusion — directly into a vein — by a trained healthcare professional, typically in a hospital or infusion center. Each dose is infused over 30 minutes. It is usually given every 6 to 8 hours, depending on the type and severity of the infection. Treatment typically lasts 7 to 14 days.

• Patients with kidney disease or on dialysis require dose adjustments — your care team will calculate the right schedule based on your kidney function.
• For hospital-acquired pneumonia caused by certain bacteria, a second antibiotic (an aminoglycoside) is given alongside it — always as a separate infusion, never mixed together.
• Pediatric dosing is based on the child's weight and age; children weighing over 40 kg receive adult doses.

The most common side effects reported in clinical trials include:

• Diarrhea (most common, reported in over 1 in 10 patients)
• Constipation
• Nausea
• Headache
• Trouble sleeping (insomnia)
• Skin rash or itching
• Vomiting
• Yeast infection (candidiasis) in the mouth or elsewhere

Most side effects are mild to moderate and temporary. However, contact your medical team immediately for any severe rash or skin blistering, watery or bloody diarrhea, signs of allergic reaction (swelling, trouble breathing), muscle pain with dark urine, signs of seizure, or any unusual bruising or bleeding — these require prompt evaluation.

• Serious allergic reactions (anaphylaxis): Potentially life-threatening allergic reactions, including shock, have occurred. Risk is higher in people with a history of allergy to penicillins, cephalosporins, or carbapenems. The infusion must be stopped immediately if a reaction occurs.
• Severe skin reactions: Rare but serious conditions including Stevens-Johnson syndrome, toxic epidermal necrolysis, and DRESS (drug reaction with eosinophilia and systemic symptoms) have been reported. Stop the medication and seek care if a rash is spreading or worsening.
• Kidney damage in critically ill patients: Clinical studies found piperacillin and tazobactam is associated with a higher risk of kidney failure in critically ill patients compared to some other antibiotics. Kidney function should be monitored; alternatives should be considered when possible.
• Muscle breakdown (rhabdomyolysis): Reported in some patients. Watch for muscle pain, weakness, or dark urine, and report these immediately.
• Seizures and nerve/muscle excitability: Can occur, especially at higher doses or in patients with kidney problems. Patients with seizure disorders need close monitoring.
• C. difficile-associated diarrhea: Like all antibiotics, this medication can disrupt normal gut bacteria and allow C. difficile to overgrow, causing diarrhea that ranges from mild to life-threatening. Report persistent or bloody diarrhea promptly.
• Low white blood cell count (leukopenia/neutropenia): More likely with prolonged therapy (21 days or more). Blood counts should be monitored during extended treatment.
• Hemophagocytic lymphohistiocytosis (HLH): A rare but severe immune reaction reported in both adults and children. Signs include fever, rash, swollen lymph nodes, and enlarged liver or spleen. Discontinue immediately if suspected.

Several medications interact meaningfully with piperacillin and tazobactam injection:

• Vancomycin: Combining these two antibiotics increases the risk of acute kidney injury — kidney function must be monitored closely if both are used.
• Aminoglycosides (tobramycin, gentamicin, amikacin): Piperacillin can chemically inactivate aminoglycosides if they are mixed together; they must always be given as separate infusions. In hemodialysis patients, tobramycin levels may drop significantly and should be monitored.
• Probenecid: This gout medication slows how fast the kidneys clear piperacillin and tazobactam, keeping them in the body longer; avoid combining unless medically necessary.
• Heparin and oral anticoagulants (blood thinners): May affect blood clotting when used with this antibiotic; coagulation tests should be checked more often.
• Vecuronium and other non-depolarizing neuromuscular blockers: Piperacillin may extend and intensify the muscle-relaxing effects of these drugs used during surgery or intensive care.
• Methotrexate: Piperacillin may slow the kidney's ability to remove methotrexate, raising its levels and the risk of methotrexate toxicity; close monitoring is required.

This is not a complete list of interactions. Always talk with your doctor or pharmacist before starting, stopping, or changing any medication.

• Penicillin or cephalosporin allergy: This medication is contraindicated if you have had an allergic reaction to any penicillin, cephalosporin, or beta-lactamase inhibitor. Tell your doctor before starting.
• Kidney disease or dialysis: Doses must be adjusted based on how well your kidneys are working; your care team will calculate the right schedule. Both hemodialysis and CAPD patients require specific dosing changes.
• History of seizures: This medication can increase seizure risk, especially in people with kidney problems or at higher doses.
• Pregnancy: Piperacillin and tazobactam cross the placenta. Human safety data are limited. Discuss the risks and benefits with your doctor.
• Breastfeeding: Piperacillin is found in human breast milk; data on tazobactam in breast milk are not available. Discuss with your doctor whether to continue breastfeeding during treatment.
• Children under 2 months: Safety and effectiveness have not been established in infants younger than 2 months.
• Older adults: More likely to have reduced kidney function, which affects how this drug is cleared. Kidney function monitoring and careful dose selection are recommended.
• Sodium-restricted diet: This medication contains a significant amount of sodium per dose, which may be relevant for patients with heart failure or other conditions requiring low sodium intake.
• Low potassium levels or use of diuretics/chemotherapy: There is a risk of low potassium (hypokalemia) with this medication; electrolytes should be monitored in at-risk patients.
• Cystic fibrosis: Patients with cystic fibrosis may have a higher rate of fever and rash with piperacillin-containing therapies.

In overdose, the most likely symptoms are nausea, vomiting, diarrhea, and — particularly if kidney function is impaired — neuromuscular excitability or seizures. Treatment is supportive and based on the patient's symptoms. Hemodialysis can help remove excess piperacillin and tazobactam from the blood if needed.

The key measure of how well piperacillin and tazobactam works is how long its concentration in the blood stays above the minimum level needed to inhibit bacterial growth — this is called the time above the MIC (minimum inhibitory concentration). The longer drug levels remain above this threshold during each dosing interval, the more effective it is at eliminating the infection. This is why the drug is given in frequent, divided doses throughout the day.

Peak blood levels of piperacillin and tazobactam are reached immediately at the end of each IV infusion. Both drugs have short half-lives — roughly 0.7 to 1.2 hours — so they clear the body relatively quickly, which is why frequent dosing is needed. Both are widely distributed throughout the body, reaching tissues including the lungs, intestinal lining, gallbladder, bile, and female reproductive organs. They are excreted primarily by the kidneys — about 68% of piperacillin and 80% of tazobactam leave the body unchanged in the urine — so kidney function directly affects how long they stay in the body and how the dose needs to be adjusted.

Prior to Reconstitution: Store at 20° to 25°C (68° to 77°F).